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Re: Treatment of Peritoneal Carcinomatosis
by Cytoreductive Surgery and Intraperitoneal
Hyperthermic Chemoperfusion (IHCP):
Postoperative Outcome and Risk Factors
for Morbidity
Peritoneal carcinomatosis results from intraperitonealdissemination of cells derived of primary tumours
from various origin. The treatment of this tumour stage is
generally palliative. Beside ovarian cancer, peritoneal
carcinomatosis from other origin does little react upon
systemic chemotherapy only. Therefore, more demand-
ing therapies are being explored. To date, one of the most
successful therapeutic concepts consists of radical sur-
gical tumor debulking followed by intraoperatively applied
intraperitoneal hyperthermic chemotherapy.
Currently several components of this therapy are under
investigation to optimize effect and to reduce side effects.
Obviously the more complete the reduction of tumor tis-
sue can be achieved, the higher the chemoconcentration
in residual tumour tissue will be. In general, a cytore-
duction to no macroscopic detectable disease or at least
a reduction to tumour nodules of <2.5mm of diameter was
the goal.1 For the intraoperative intraperitoneal chemo-
therapy the abdominal cavity can be temporarily closed or
left open. The latter has the advantage that local hyper-
thermia and chemoperfusion within the peritoneal cavity
will be more homogeneous.2
Based on the experience with the treatment of the
pseudomyxoma peritoneii, using Mitomycin C in combi-
nation with 5-FU as chemotherapeutic agents. However,
the effect on colorectal cancer is limited and recently
Oxaliplatin and Irinotecan have been used for intraperi-
toneal therapy in these diseases.3,4 Furthermore, for
mesotheliomas and ovarian cancer related peritoneal
carcinomatosis, Paclitaxel can be used successfully, as
local peritoneal tissue concentrations exceeds 103 times
compared to the concentrations achieved with intrave-
nous application of the drug.5
In the present issue, Roviello et al.6 (DOI: 10.1007/
s00268-006-0038-0) report their experience (N = 61) with
cytoreduction and intraperitoneal hyperthermic chemo-
perfusion and present their outcome and morbidity. In
their series, the authors confirm that the median survival
is potentially by far better after this complex therapeutic
strategy, than following systemic chemotherapy only.
However, if this is the effect of aggressive cytoreduction
or if it can be attributed to the intraperitoneal, chemo-
therapy is still open.
As expected and confirmed by this study, age (RR
1.06 per year) is a significant risk factor for complications
following the presented therapy.6 One would expect ex-
tent of disease, visceral anastomosis or extent of resec-
tion (peritonectomy, time of duration of the procedure) as
additional significant risk factors for morbidity. However
completeness of cancer resection (CCR 2/3 versus CCR
0/1: RR 9.27) showed to have highest impact upon
complication frequency in the present patient series.6 In
cases where complete cytoreduction could to be
achieved (CCR 2/3) the fact of high morbidity may reflect
the difficulty or ‘‘risk taking’’ of the surgical procedure to
reduce tumour tissue to the desired extent in the
individual patient.
In summary, Roviello et al.6 have highlighted the
advantage of surgical cytoreduction in combination with
intraperitoneal hyperthermic chemotherapy in respect of
survival as well as the risk factors related to complica-
tions. However, the treatment of peritoneal carcinoma-
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tosis is demanding, associated with substantial morbidity
and is still under investigation for further improvements
and therefore should only be done in tertiary referral
centres preferentially within study protocols.
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